Related Experiment Video
Updated: May 29, 2026
Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Oxygen is a master regulator of the immunogenicity of primary human glioma cells
Michael R Olin1, Brian M Andersen, Adam J Litterman
1Department of Pediatrics, Graduate Program in Neuroscience, Biostatistics and Bioinformatics, University of Minnesota, Masonic Cancer Center, Minneapolis, Minnesota, USA.
Abstract:
With recent approval of the first dendritic cell (DC) vaccine for patient use, many other DC vaccine approaches are now being tested in clinical trials. Many of these DC vaccines employ tumor cell lysates (TL) generated from cells cultured in atmospheric oxygen (∼20% O₂) that greatly exceeds levels found in tumors in situ. In this study, we tested the hypothesis that TLs generated from tumor cells cultured under physiologic oxygen (∼5% O₂) would be more effective as a source for DC antigens. Gene expression patterns in primary glioma cultures established at 5% O₂ more closely paralleled patient tumors in situ and known immunogenic antigens were more highly expressed. DCs treated with TLs generated from primary tumor cells maintained in 5% O₂ took up and presented antigens to CD8 T cells more efficiently. Moreover, CD8 T cells primed in this manner exhibited superior tumoricidal activity against target cells cultured in either atmospheric 20% O₂ or physiologic 5% O₂. Together, these results establish a simple method to greatly improve the effectiveness of DC vaccines in stimulating the production of tumoricidal T cells, with broad implications for many of the DC-based cancer vaccines being developed for clinical application.
Insights
Culturing tumor cells at physiologic oxygen levels (5% O₂) enhances tumor cell lysates (TL) for dendritic cell (DC) vaccines. This improves antigen presentation and generates more effective tumor-killing CD8 T cells for cancer immunotherapy.
Area of Science:
- Oncology
- Immunology
- Biotechnology
Background:
- Dendritic cell (DC) vaccines are a promising cancer immunotherapy approach, with recent approvals for patient use.
- Current DC vaccine production often uses tumor cell lysates (TL) from cells cultured at atmospheric oxygen (20% O₂), which is physiologically inaccurate for tumor microenvironments.
- Tumor oxygen levels in situ are significantly lower (∼5% O₂) than standard culture conditions.
Purpose of the Study:
- To investigate if tumor cell lysates (TL) generated under physiologic oxygen (5% O₂) are more effective for dendritic cell (DC) vaccine development compared to those cultured at atmospheric oxygen (20% O₂).
- To determine the impact of oxygen levels during TL generation on antigen expression, DC uptake, antigen presentation, and subsequent T cell-mediated tumor killing.
Main Methods:
- Primary glioma cultures were established and maintained under either atmospheric (20% O₂) or physiologic (5% O₂) oxygen conditions.
- Gene expression analysis was performed to compare cultures.
- Dendritic cells (DCs) were treated with TLs generated from tumor cells cultured under different oxygen conditions.
- DC antigen uptake and presentation to CD8 T cells were assessed.
- The tumoricidal activity of primed CD8 T cells was evaluated against target tumor cells cultured under both 20% O₂ and 5% O₂.
Main Results:
- Primary glioma cultures maintained at 5% O₂ exhibited gene expression patterns more closely resembling patient tumors in situ.
- Higher expression of known immunogenic antigens was observed in tumor cells cultured at 5% O₂.
- DCs treated with 5% O₂-derived TLs demonstrated more efficient antigen uptake and presentation to CD8 T cells.
- CD8 T cells primed with 5% O₂-derived TLs showed superior tumoricidal activity against tumor cells under both atmospheric and physiologic oxygen conditions.
Conclusions:
- Generating tumor cell lysates (TL) under physiologic oxygen (5% O₂) significantly enhances their effectiveness as a source for dendritic cell (DC) vaccine antigens.
- This simple method improves DC vaccine efficacy by promoting more efficient antigen presentation and generating potent tumoricidal CD8 T cells.
- These findings have broad implications for improving the clinical application of numerous DC-based cancer vaccines currently under development.
